Dataset Information

Body surface area capping may not improve cytotoxic drugs tolerance.

ABSTRACT: Capping body surface area (BSA) at 2 m² is a routine clinical practice. It aims at reducing toxicities in over 2 m² BSA patients. 455,502 computerized chemotherapy prescriptions made between 2011 and 2017 were taken from BPC software. Chemotherapy computerized order entry is created by a senior physician prescribers before patient consultation. Only prescriptions with dose calculation involving BSA were selected. 51,179 chemotherapy prescriptions were analyzed; corresponding to 7206 patients who received intravenous chemotherapy. The number of chemotherapy prescriptions in over 2 m² BSA patients was nearly the same in the hematology as in the oncology departments. But, 79.1% of prescriptions were capped at 2 m² in the oncology department contrary to 21.9% in the hematology department. Practices analysis showed more dose limitation in palliative situations in both departments. Unexpectedly, 6.53% of capped prescriptions were performed in patients with normal BMI. The patients who received capped doses of chemotherapy had neither fewer dose reductions due to toxicity nor deterioration of their general condition. Capping did not induce fewer dose reductions in patients with BSA greater than 2 m². Prospective studies in this population are needed to standardize chemotherapy administration in population with BSA?>?2 m².

SUBMITTER: Bouleftour W

PROVIDER: S-EPMC7843991 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Body surface area capping may not improve cytotoxic drugs tolerance.

Bouleftour Wafa W Viard Agathe A Mery Benoite B Chaux Robin R Magne Nicolas N Simoens Xavier X Rivoirard Romain R Forges Fabien F

Scientific reports 20210128 1

Capping body surface area (BSA) at 2 m<sup>2</sup> is a routine clinical practice. It aims at reducing toxicities in over 2 m<sup>2</sup> BSA patients. 455,502 computerized chemotherapy prescriptions made between 2011 and 2017 were taken from BPC software. Chemotherapy computerized order entry is created by a senior physician prescribers before patient consultation. Only prescriptions with dose calculation involving BSA were selected. 51,179 chemotherapy prescriptions were analyzed; correspondin ...[more]

PMID: 33510207

Similar Datasets

Project description:Background:Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking. Therefore, we analyzed the toxicity and effectiveness of fixed-dose capecitabine and compared this strategy with a BSA-based dose of capecitabine in a large set of patients. Methods:Patients treated with fixed-dose capecitabine between 2003 and 2015 were studied. A comparable group of patients, dosed based on BSA, was chosen as a control cohort. A total of two combined scores were used: capecitabine-specific toxicity (diarrhea, National Cancer Institute Common Toxicity Criteria grade ?3, hand-foot syndrome ?2, or neutropenia ?2), and clinically relevant events due to toxicity, that is, hospital admission, dose reduction, or discontinuation. Per treatment regimen, patients were divided into three BSA groups based on BSA quartiles corrected for sex. Toxicity scores were compared by a Chi-square test between cohorts, and within cohorts using BSA groups. Progression-free survival (PFS) was estimated by the Kaplan-Meier method. Results:A total of 2319 patients were included (fixed dosed, n = 1126 and BSA-based dose, n?=?1193). Overall, four regimens were evaluated: capecitabine-radiotherapy (n = 1178), capecitabine-oxaliplatin (n = 519), capecitabine triplet (n = 181) and capecitabine monotherapy (n = 441). The incidence of capecitabine-specific toxicity and clinically relevant events was comparable between fixed-dose and BSA-dosed patients, while a small difference (7.1%) in absolute dose was found. Both cohorts showed only a higher incidence of both toxicity scores in the lowest BSA group of the capecitabine-radiotherapy group (p < 0.05). Subgroups of the fixed-dose cohort analyzed for PFS, showed no differences between BSA groups. Conclusions:Fixed-dose capecitabine is as comparably well tolerated and effective as BSA-based dosing and could be considered as a reasonable alternative for BSA-based dosing.

Dataset Information

Body surface area capping may not improve cytotoxic drugs tolerance.

Publications

Body surface area capping may not improve cytotoxic drugs tolerance.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets